Urist Marshall

EVP Urist Marshall sells 41,576 shares (84.9% of holdings) at $39.15 after sell on 2025-12-01

Urist Marshall, EVP of Research & Investments, executed 2 separate sales totaling 41,576 shares for $1,627,814.99 on 2025-12-05, reducing his holdings from 49.0K shares to 7.4K shares. This represents an 84.9% reduction in his position at $39.15 per share, just 1 trading day after two prior sales on 2025-12-01. The pattern of consecutive-day selling of large tranches suggests a deliberate effort to exit a concentrated position, with the blended transaction price of $39.15 representing a premium to the current market price of $38.09. The company's revenue decline of 3.9% year-over-year and elevated P/E of 19.34 provide context for the execution timing, though the outcome of his 2025-12-01 sales remains unmeasurable at the 30- and 90-day marks.

EVP Urist Marshall sold 41,575 shares of RPRX for $1,659,488.82 in two separate transactions on 2025-12-01 at blended average price $39.92

Urist Marshall, EVP of Research & Investments, executed two separate open-market sales on 2025-12-01, selling 23,333 shares at $39.93 and 18,242 shares at $39.90, totaling 41,575 shares for $1,659,488.82. This represents a 61.9% reduction in his post-transaction holdings, bringing them from 67,215 shares to 25,640 shares. The sale prices of $39.92 (blended average) occurred within the 52-week range of $24.28–$40.78 and near the current price of $39.60, suggesting execution in a relatively tight band. The size and concentration of the sale—a substantial portion of his prior holdings liquidated in a single-day, two-tranche event—warrant investor attention regarding the motivation behind this substantial reduction in executive ownership.